Results: TTR increased with increasing age, peaking around 77% at 70-75 years, and then declined, was lower in females than males, and in dependent home-monitored patients than those attending clinic (P < 0.0001). TTR, number of dose changes and INR monitoring events and the probability of TTR ≤ 65%, differed across the centres (P < 0.0001).
| INTRODUC TI ON
Trial data of patients with atrial fibrillation (AF) taking warfarin indicate that quality of warfarin use, as measured by average time in the standard target range (TTR) of 2.0-3.0 influences both risk of major bleeding and thromboembolic events. 1 Similar benefits in terms of preventing stroke or systemic embolism have been noted both in patients treated with non-vitamin K antagonist oral anticoagulants (NOACs) and those treated with warfarin with high TTR, 2 with no differences between the treatments in rates of
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thromboembolic or thrombotic events where, in warfarin-treated patients, mean TTR was 70%. 3 As a result of these findings, interpolated TTR 4 has become a standard measure of quality of warfarin management. Unfortunately, many vitamin K antagonist (VKA)-treated patients do not achieve a TTR of >70%, with a meta-analysis of published data suggesting that patients spend an average of 61%, 25% and 14% of their time within, above and below range, respectively. 5 This is important as patients with an individual TTR of less than 70%, or high INR variability, have an increased rate of major bleeding or thromboembolism 6 ; those with a TTR of >70% have a 79% reduced risk of stroke compared with those with <30% TTR, and mortality rates are significantly lower in those with a TTR >70% than those not achieving this. 7 57% of thrombotic events and 42% of haemorrhage events occur at an INR of <2.0 and >3.0, respectively. 5 Factors influencing TTR are both individual based (iTTR) and centre based (cTTR), with iTTR significantly predicting risk of major haemorrhage, ischaemic stroke and all-cause mortality and cTTR being a weak predictor of all-cause mortality. 8 Identification of the influences upon these outcomes is important to ascertain which ones are modifiable and improvable.
Patient factors known to predict poor INR control include age less than 60 years, female sex and having more than 2 comorbidities, factors which have been included in the SAME-TT2R2 score aimed at aiding decision making between a NOAC and a VKA, 9 heart failure 10 and severe chronic kidney disease. 11 In an earlier longitudinal study of anticoagulation control, we demonstrated a biphasic relationship with age, TTR peaking at 67 years, being poorer in females than in males, and in patients monitored at home due to dependency and immobility than in those attending monitoring clinic. 12 Vitamin K antagonist monitoring setting influences TTR with patients managed in anticoagulation clinics and with adherence to a warfarin dosing algorithm having better control and outcomes than those managed in community settings. 8, 13, 14 Thus, for example, patients in North America spend significantly less time in the therapeutic range than those in Europe, where results are best in Sweden, then the United Kingdom (UK), 5 both of which have a similar anticoagulant management system. In the United States (US), however, only about one-third of patients have access to an anticoagulant clinic, 15 and other strategies which can improve TTR for some patients such as self-monitoring are less used. 16 We set out to investigate the impact of age, gender and differences between management systems (hospital, general practice and domiciliary) on anticoagulation control in seven UK-based centres to determine to what extent our earlier observations of age-related effects upon %TTR were replicable elsewhere, and to examine any differences in centre-based TTRs which might be indicative of system-based differences in management which could potentially be addressed to enhance the quality of anticoagulation control, as many of the patient factors influencing TTR are fixed and may not be easily amenable to change by targeted interventions.
| PATIENTS , MATERIAL S AND ME THODS
The study involved audit of anonymised electronic data held by 7 centres across the UK using the DAWN computer dosing programme (version 6.10, Milnthorpe, Cumbria, UK), 17 and as such, 
| Statistical analysis
The Since some data had a polynomial pattern, for later analysis quadratic, cubic, quartic and linear regression models were applied to examine the effect of age for all the variables tested.
Weighted analysis was used in all statistical calculations because of the large variation in sample sizes across age groups.
Individual observations were also analysed using random effects to take account of the longitudinal nature of the data. This form of analysis was more complex due to the non-normal nature of the data. The same conclusions were obtained and so the analysis of means is presented here as the interpretation of the analysis is much more straightforward. The probability of a TTR ≤ 65%
according to age was determined using binary logistic regression analysis. Quartic regression models were used to examine the effect of age on gender, monitoring centre and monitoring setting.
Data were analysed using Minitab statistical software (version 17.0) and R statistical package. Data are presented as mean ± SD unless stated otherwise. and 7, patients were recorded as being monitored either at "hospital," "GP" or "home." For centres 1 and 4, patients were monitored at either "home" or "GP," and for centre 5 at "GP" only. The clinic monitoring system description and the number of patients monitored and their mean age at each of the individual centres according to setting are presented in Tables 1 and 2, Warfarin dose requirement fell with increasing age (P < 0.0001, quartic regression), with age accounting for 99.7% of the variability in dose requirement. Hospital and GP-monitored patients were prescribed a significantly higher mean warfarin dose than those monitored at home for most ages, the reverse being true for age less than 55 (P < 0.0001). For the whole population, both the mean number of dose changes (as square root) (P < 0.0001, R 2 = 96%, quartic regression) and the mean number of INR monitoring events (as square root) (P < 0.0001, R 2 = 95%, cubic regression) were significantly related to age ( Figure 2 ).
| RE SULTS
There was a highly significant difference in both the number of INR measurements (square root; P < 0.0001, R 2 = 90%, cubic regression) and warfarin dose changes (P < 0.0001, R 2 = 93%, quartic regression) between the 7 study centres (Table 3) . TTR was found to be highly significantly different between the seven centres (P < 0.0001, R 2 = 93%, quartic regression). Centre 5 had the highest TTR and probability of having a TTR ≥ 65% and centre 6 the lowest (P < 0.001), particularly for patients aged over 80 years. Percentage time above (P < 0.0001, R 2 = 91%, cubic regression) and below target INR range (P < 0.0001, R 2 = 82%, quartic regression) was highly significantly different between the seven centres; centre 5 had the lowest %time above target INR range, and centre 3 the highest. Centres 5 and 7 had the two lowest %time below target INR range; centre 6 had the highest, contributed to by warfarin doses which were significantly lower than those recorded at the other study centres (P < 0.0001, R 2 = 99%, quartic regression);
( Figure 3 ).
In females, the mean TTR was marginally lower (by 1.12%; P < 0.0001), and both the mean %time below (0.57%, P < 0.0001) and above target INR range (0.53%, P < 0.0001) were marginally higher compared to males. Female patients had a marginally higher number of recorded INR checks (P < 0.0001). Warfarin doses for females were significantly lower than those for males (P < 0.0001), and they had more dose changes (P < 0.0001) than their male counterparts. In spite of this, females had a slightly higher probability of having a TTR ≤ 65% (P < 0.0001, quartic regression) compared to males, with centre 6 having the highest probability and centre 5 the lowest (P < 0.0001, quartic regression).
The TTR of patients monitored at hospital and GP settings exceeded that of those monitored at home by 3.7% whereas, for the %time above and below target INR range, patients monitored at home exceeded those monitored at hospital and GP by 1.6% and 2.1%, respectively (P < 0.0001), but with a non-interacting effect with age.
Patients monitored at home had a greater frequency of INR checks and warfarin dose changes (by 0.24 and 0.26 of squared root values, respectively) but (with the exclusion of centres 5 and 6 as centre 5 has no home-monitored system in place and there was a small number of home-monitored patients at centre 6), nevertheless, had a markedly greater probability of having a TTR ≤ 65% compared to hospital and GP monitored patients; ~10% greater across most ages.
| D ISCUSS I ON
In this study, we were able to follow-up longitudinally 25 270 patients (amounting to 203 220 patient years of observation) across 7 different centres and establish that there is a consistent pattern of the effects of age and gender and dependency upon TTR, it peaking at around 70-75 years, being lower in females than in males and in individuals requiring home monitoring than those attending clinic, whilst there are considerable differences between the centres in quality of anticoagulant control achieved. Achieving good anticoagulation control is important in optimising outcomes in AF patients taking warfarin, with risks of death, MI, major bleeding, stroke or systemic embolism being related to anticoagulation control. 18 Using data from the ARISTOTLE, ROCKET AF and RELY trials of use of apixaban, rivaroxaban and dabigatran, respectively, it has been estimated that, among non-valvular AF patients, each 10% increase in TTR in warfarin treated patients correlates with a 0.32% per year decrease in stroke/systemic embolism rate, but it has no effect on major bleeding. 19 As noted in our previous single centre longitudinal study, 12 we have confirmed a consistent curvilinear relationship between TTR and age across all the three monitoring settings (hospital, GP and domiciliary) in the 7 studied centres at 6 different geographical This curvilinear pattern was found for percentage of time both above and below range. The probability of having a TTR ≤ 65%
increased over the age of 70 years, and control across centres was, as in our previous study, 12 consistently worse in females than in males and in those monitored at home rather than clinic who had lower TTRs and spent more time both above and below their target range, in spite of greater frequency of INR checks and warfarin dose changes. Anticoagulated female AF patients show a slightly higher rate of ischaemic stroke than male patients, 20 even after adjusting for TTR, 21 suggesting the potential of a higher net clinical benefit of anticoagulant treatment in females, which is not being achieved. The greater risk of ischaemic stroke in women, in part related to females spending more time outside and below the therapeutic range than men, 9, 22 suggests that they might benefit from a more aggressive VKA management, or anticoagulation with a NOAC, as these drugs have similar efficacy and bleeding risk in women and men. 23 The variability of cTTR is remarkable: a meta-analysis reported a range from 40% to 78% in US-based primary studies 24 and even in randomised controlled trials variability ranged from 44% to 77%. 25 This is important as the benefit from the VKA oral anticoagulants is dependent upon TTR. In AF patients, a 10% increase in time out of the therapeutic range is associated with an increase in the odds ratio of ischaemic stroke of 1.10, P = 0.006, 26 and a population-average model predicted that a minimum TTR of 58% would be needed to be confident that patients would benefit from treatment. 1 NOACs show a greater relative reduction in major bleeding, mainly driven by a reduction in haemorrhagic stroke compared to warfarin therapy when cTTR is <66%, whereas the benefits of NOACs over warfarin become less apparent when cTTR is ≥66%. 27 As warfarin will continue to be used for many AF patients including those with rheumatic valvular disease, prosthetic heart valves or those with severe kidney disease, it is important to identify features of management which achieve excellence in anticoagulant control for sharing and adoption by currently less successful anticoagulation monitoring centres as achieving even a small percentage improvement in TTR would be of benefit to a large absolute number, given the estimated prevalence of AF in the general population of approximately 1%; 2.2 million people in the U.S. and 4.5 million in the European Union. 28 Variation in dose adjustment practice between each centre has been associated with cTTR, as well as differences in mean target INR levels. 29 In our study, we controlled for the latter by selecting data only from patients with a target range of 2.0-3.0. Other influences are participation in external assessment of therapy quality. 30 Internal quality check was performed daily and external quality assurance undertaken monthly through National External Quality Assessment Service (NEQAS), Sheffield, UK at all the participating anticoagulation centres.
Important influences upon cTTR are that patients managed in a community setting have poorer control of anticoagulation when compared to those managed in an anticoagulant clinic or a RCT setting. 5 Dose adjustments by clinicians, based upon experience, tend to under-dose patients, whereas adherence to warfarin dosing algorithms is effective in improving anticoagulation control. 31, 32 In the RELY study, the degree of adherence accounted for 87% of the variation between participating centres and 55% of the between-country variation in TTR. 25 Each 10% increase in the consistent use of dosing algorithm by centre independently predicted a 6.12% increase in TTR and an 8% decrease in the rate of the composite clinical outcome. 25 Varying degrees of non-adherence to clinical guidelines is expected; in one study of USA veterans, none of the 5 sites studied were particularly adherent, with consistent patterns of concordant and discordant management in terms of dose changes and follow-up intervals being noted. 33 Although all the participating centres in our study were ostensively following a standard warfarin dosing algorithm, variation in dose adjustment practice across the 7 centres must account for some of the observed differences in the study results between centres. As systems employing algorithm-based dosing and promoting adherence to them could improve clinical outcomes on a global scale, feedback to centres to improve patient outcomes by practising in a more guideline concordant manner is recommended. Anticoagulation management can be effectively carried out by a range of staff members; indeed there is strong evidence that community management utilising computer-assisted dose adjustment can improve when led by pharmacists rather than primary care general practitioners; TTR improving from 71.4% to 84.1% in one New Zealand based study in spite of no increase in point of care
INR testing. 34 The 80% adherence to the algorithm by pharmacists compared to the 70% adherence by doctors was the most important factor influencing TTR rather than the specific details of the algorithm. Poorer control achieved by doctors compared to pharmacists (TTR 67.4% vs 75.1%) in another study was related to poorer adherence to computer dosing recommendations by doctors, with doctors over-riding the algorithm up to 50% of the time when INR was below range and tending to under-dose patients, mistakenly believing their own dose adjustments were better than the computer program which had been developed using large amounts of patient data. 35 Although this perhaps reflects inherent concern about the risk of bleeding in poorly controlled patients it will have achieved poorer outcomes as a meta-analysis has shown that a 6.9% improvement in TTR may reduce major haemorrhage by one event per hundred patient years of treatment. 36 Centre 6 in our study, which used the lowest doses and had the highest %TTR below range and the highest probability of TTR < 65%, with comparable mean number of INR monitoring events and dose changes per patient per year to other centres (Table 2) to improving their quality, none of our centres was regularly provided with such feedback. We suggest that correcting this might be helpful, both to the centre to improve anticoagulation control overall and also to give each patient and his or her clinician knowledge of the individual's TTR over the previous 6 month period of VKA therapy to facilitate ongoing informed decision making about the choice of most appropriate oral anticoagulant. As whilst nearly 60% of AF patients on warfarin therapy with a TTR ≥ 70% will maintain this over the next 6 months, for a substantial minority TTR will deteriorate; the UK National Institute for Health and Care Excellence (NICE) recommends reassessment of anticoagulation for people with a TTR < 65% over a maintenance period of at least 6 months, 37 we were unable to assess the extent to which differences in levels of co-morbidities and concurrent drug therapy were contributing to differences noted between centres, as data on these covariates were unavailable through the DAWN programme. This is regrettable as, although confounders are not fully elucidated, patient-level characteristics are known to contribute to variability in TTR. Of the 42 variables noted to have some influence upon TTR, the 6 clinical variables of pneumonia, renal dysfunction, prior bleeding, hospitalisation, pain medication and antibiotic use were particular confounders, but lack of a dedicated anticoagulation service with a structured approach to warfarin management was found to be the strongest predictor of poor TTR. 38 In contrast, whilst comorbidities, medications, hospitalisations and ethnicity were shown in a study of 100
Veterans' Health Administration sites to account for 13.3% of the variability in TTR, site-level variability explained only 2.9%.
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In conclusion, the results of this study of 7 UK monitoring centres are consistent with those of our previous study in 1 centre 
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